My blog has moved!

You should be automatically redirected in 6 seconds. If not, visit
http://www.shockmd.com
and update your bookmarks.

Showing posts with label drug companies pharmacy. Show all posts
Showing posts with label drug companies pharmacy. Show all posts

Tuesday, February 19, 2008

Lack of Proper Evaluation of Curricula about resident-phamaceutical industry interaction


9 Curricula were identified in a literature search for curricula addressing resident-pharmaceutical industry relationship. Lack of experience may make young doctors particular vulnerable to pharmaceutical industry influence. These interactions between doctor and pharmaceutical companies have an impact on doctor knowledge and prescribing practice. The pharmaceutical companies have different and efficient marketing techniques to influence doctors. Residents may be even more influenced when not educated about these threats.

Inconsistency in content (of the curricula), application and evaluation methodology prevents any meaningful synthesis of data


This was the conclusion of a systematic review of the curricula.

The literature search obtained 121 articles, of which 78 did not address relationships between doctors and the pharmaceutical industry. 10 were selected for detailed review. Only 9 could be used and only 8 included an evaluation component of which only 1 included a control group. Only 2 evaluations used a validated outcome instrument, and no studies included longterm follow-up. Modest improvement were noted in residence confidence, knowledge of guidelines.

A lot remains to be done. More curricula with better education are needed. Standardization of evaluation for establishing change in attitude and behaviors are also needed.
ResearchBlogging.org

T Montague, B., Fortin VI, A.H., Rosenbaum, J. (2008). A systematic review of curricula on relationships between residents and the pharmaceutical industry. Medical Education, 42(3), 301-308. DOI: 10.1111/j.1365-2923.2007.02998.x



Thursday, November 1, 2007

Doctors and Drug Companies — Scrutinizing Influential Relationships


An Editorial for perspective in the New England Journal of Medicine about the relationship between drug companies and physicians.

Indeed, the nature, extent, and consequences of physicians' relationships with industry have become one of the most fiercely debated issues in health care today. At the simplest level, such a relationship exists whenever a physician accepts anything from a company whose products or services are related to the practice of medicine. And such interactions are ubiquitous: according to a recent survey, although the frequency and intensity of the ties vary according to physicians' personal and professional characteristics, virtually all physicians (94%) have some type of relationship with industry. Most commonly, physicians report receiving food and beverages in the workplace (83%) or being given drug samples by a manufacturer's representative (78%). More than one third of physicians (35%) receive reimbursement for costs associated with professional meetings or continuing medical education, and more than one quarter (28%) receive payments for consulting, speaking, or enrolling patients in trials


A related article in the NEJM is about: A National Survey of Physician–Industry Relationships
The conclusion drawn from the survey is: The results of this national survey indicate that relationships between physicians and industry are common and underscore the variation among such relationships according to specialty, practice type, and professional activities.
Free text available
Psychiatrists are not mentioned.



Saturday, July 7, 2007

Direct To Consumer Advertising of prescription drugs, a threat to Europe?

drug advertising
The European Committee supports the request of the pharmaceutical companies for "direct-to-consumer-advertising". The International Society of Drug Bulletins warns against this legislation. It is wrong to confuse information with advertising.
The dangers of "direct-to-consumer-advertising" are:
1. advertisements from drug companies are mostly limited to those drugs with the highest profit
2. efficacy is often exaggerated
3. risks are usually obscured
4. it confuses patients when suggested another drug by their physicians
5. it forces physicians to use the advertised drug
6. advertisements by drug companies lack comparison with drugs from other companies or other treatments, making it hard for consumers to compare different drugs or other treatment options

Another objection is the impartiality of the Pharmaceutical Forum preparing this proposal. This is done by the Pharmaceutical Forum. This forum is not elected and not less than 5 drug companies are part of this forum. Moreover the patients are represented by The European Patients' Forum sponsored by the Drug Companies.
There are only two countries allowing "direct-to-consumer-advertising": USA and New Zealand.